Skip to main content
Premium Trial:

Request an Annual Quote

Co-Diagnostics Files to Sell Up to $25M in Stock

NEW YORK (GenomeWeb) — Co-Diagnostics announced today that it has filed with the US Securities and Exchange Commission to sell up to $25 million of its shares.

The filing was made as a Form S-3 shelf registration statement, and follows Co-Diagnostics' close of a $2 million non-convertible debt instrument earlier this month. In that transaction, the company issued one of its shareholders a $2 million promissory note in exchange for a loan for the same amount.

Last month, Co-Diagnostics also received CE marking for its Logix Smart MTB Test for diagnosing tuberculosis.

"This Form S-3 shelf registration statement enhances the company's financial flexibility in the event appropriate opportunities present themselves," Co-Diagnostics CEO Dwight Egan said in a statement.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.